GO:0006376 mRNA splice site recognition: Spliceosome Assembly Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006376 (mRNA splice site recognition) is the biological process in which components of the assembling spliceosome select a splice site, corresponding to formation of the commitment/E complex.
• The process begins with U1 snRNP recognizing the 5' splice site through sequential binding and modulation, while U2AF and associated factors engage the 3' splice site.
• FUBP1 acts as a general splicing factor that facilitates 3' splice site recognition and the splicing of long introns.
• Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing, linking splice site recognition to transcription.
• Defects in splice site recognition contribute to disease, including TDP-43 proteinopathies via STMN2 cryptic splice-polyadenylation and CHEK2-associated cancer risk.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of splice site recognition genes and their variants.
Description
GO:0006376, mRNA splice site recognition, is the biological process defined as the selection of a splice site by components of the assembling spliceosome. This step is foundational for accurate pre-mRNA splicing because it determines which exon junctions are formed and thus which protein isoforms are produced. The term encompasses the formation of the spliceosomal commitment complex, also known as the E complex, which commits a pre-mRNA to the splicing pathway. In practical terms, splice site recognition is the molecular decision point where the spliceosome reads the 5' and 3' splice site signals and pairs them correctly. Mechanistically, splice site recognition involves the U1 snRNP at the 5' splice site and U2AF together with associated factors at the 3' splice site, followed by dynamic rearrangements that define two phases of cotranscriptional splicing. Structural and biochemical studies have revealed a sequential binding mechanism for 5' splice site recognition and modulation by the human U1 snRNP, and a structural basis for 5' splice site recognition by the minor spliceosome. In addition, FUBP1 has been identified as a general splicing factor that facilitates 3' splice site recognition and splicing of long introns. For researchers, GO:0006376 matters because misregulation or mutation of splice site recognition components can cause disease. For example, TDP-43 proteinopathies involve STMN2 cryptic splice-polyadenylation, and CHEK2 splice-site variants have been systematically analyzed for clinical classification. Understanding this process therefore informs both basic splicing biology and therapeutic development.
mRNA splice site recognition At A Glance
| GO ID | GO:0006376 |
|---|---|
| GO term | mRNA splice site recognition |
| Ontology | biological_process |
| Definition | Selection of a splice site by components of the assembling spliceosome. |
| Synonym | spliceosomal commitment complex biosynthesis; spliceosomal commitment complex formation; spliceosomal E complex biosynthesis; spliceosomal E complex formation |
| Major function | Recognition and selection of 5' and 3' splice sites during spliceosome assembly, committing pre-mRNA to splicing |
| Key complexes | U1 snRNP, U2AF, commitment/E complex |
| Related factors | FUBP1, STMN2, CHEK2 |
| Process context | Cotranscriptional pre-mRNA splicing with dynamic U2AF cycling |
What Is GO:0006376?
In my own words, GO:0006376 describes the step in which the assembling spliceosome chooses a splice site on a pre-mRNA. It is not the chemistry of the splicing reaction itself, but the recognition and commitment phase in which spliceosomal components identify and select the 5' and 3' splice sites, leading to formation of the commitment/E complex. This process is synonymous with spliceosomal commitment complex biosynthesis/formation and spliceosomal E complex biosynthesis/formation.
Why Is mRNA splice site recognition Important in Cell Biology?
mRNA splice site recognition is important because it sets the accuracy of exon definition and determines the proteome diversity generated by alternative splicing. Errors at this step can produce cryptic splice products, as seen for STMN2 in TDP-43 proteinopathies, or clinically relevant splice-site variants such as those in CHEK2. Because the process is coupled to transcription through dynamic U2AF cycling, it also integrates transcriptional and splicing regulation. Consequently, splice site recognition is a central node for understanding gene regulation and for interpreting disease-associated variants.
• Defines exon junctions and protein isoform output during pre-mRNA splicing.
• Commits pre-mRNA to the splicing pathway via the commitment/E complex.
• Involves U1 snRNP 5' splice site recognition and modulation.
• Requires U2AF and associated factors for 3' splice site recognition.
• FUBP1 facilitates 3' splice site recognition and splicing of long introns.
• Links to cotranscriptional splicing through dynamic U2AF cycling.
• Dysregulation contributes to TDP-43 proteinopathies via STMN2 cryptic splice-polyadenylation.
• Splice-site variants in CHEK2 are clinically relevant and can be classified using minigene assays.
• Minor spliceosome 5' splice site recognition has a defined structural basis.
• Provides targets for CRISPR-based functional dissection of splicing factors.
What Happens During mRNA splice site recognition?
Commitment and E complex formation
In simple terms: The cell first marks a pre-mRNA as ready for splicing by assembling an early commitment complex.
mRNA splice site recognition begins with formation of the spliceosomal commitment complex, also called the E complex, which commits the pre-mRNA to the splicing pathway. This early recognition step is mediated by components of the assembling spliceosome and is synonymous with spliceosomal commitment complex biosynthesis/formation. The E complex represents the initial selection of splice sites before catalytic activation.
5' splice site recognition by U1 snRNP
In simple terms: A small RNA-protein machine called U1 snRNP reads the start of the intron.
The human U1 snRNP recognizes the 5' splice site through a sequential binding mechanism that allows recognition and modulation. Structural studies of the minor spliceosome have further defined the structural basis of 5' splice site recognition. Together, these studies show that 5' splice site selection is an active, regulated recognition event rather than simple base pairing.
3' splice site recognition by U2AF and FUBP1
In simple terms: Other factors read the end of the intron and help define where splicing should occur.
At the 3' splice site, U2AF and associated factors participate in recognition, and dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing. FUBP1 acts as a general splicing factor that facilitates 3' splice site recognition and splicing of long introns. These findings indicate that 3' splice site recognition is coupled to transcription and is particularly important for long introns.
Splice site pairing and commitment to splicing
In simple terms: The two ends of the intron are brought together so the spliceosome can proceed.
Initial splice-site recognition and pairing during pre-mRNA splicing involves communication between the 5' and 3' ends of the intron. The spliceosome is a dynamic RNP machine whose design principles support ordered assembly and rearrangement during recognition. This pairing step ensures that the correct splice sites are joined before catalysis.
Cotranscriptional coupling and regulation
In simple terms: Splice site recognition happens while the RNA is still being made.
Dynamic U2AF cycling links splice site recognition to transcription, defining two phases of cotranscriptional pre-mRNA splicing. This coupling means that splice site recognition is not a post-transcriptional afterthought but is integrated with RNA synthesis. Such integration helps explain how splicing fidelity is maintained in cells.
Key Genes Involved in GO:0006376 mRNA splice site recognition
The following genes and proteins are experimentally implicated in mRNA splice site recognition and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| U1 snRNP components | Recognize the 5' splice site via sequential binding | Structural and biochemical studies of 5' splice site recognition |
| U2AF | 3' splice site recognition and dynamic cycling during cotranscriptional splicing | Defines two phases of cotranscriptional pre-mRNA splicing |
| FUBP1 | General splicing factor facilitating 3' splice site recognition and long intron splicing | Model for long intron splicing and 3' splice site selection |
| STMN2 | Target of cryptic splice-polyadenylation in TDP-43 proteinopathies | Disease-relevant readout of splice site recognition defects |
| CHEK2 | Splice-site variants analyzed for clinical classification | Minigene-based splicing analysis of 52 variants |
| TDP-43 | RNA-binding protein linked to cryptic splice-polyadenylation | Neurodegeneration model for splice site recognition |
| Minor spliceosome components | 5' splice site recognition with defined structural basis | Structural studies of minor spliceosome recognition |
| Spliceosomal commitment complex factors | Form the E complex that commits pre-mRNA to splicing | Early recognition and pairing studies |
| Spliceosome core components | Dynamic RNP machine for ordered assembly | General framework for splice site recognition |
| U2AF cycling regulators | Modulate cotranscriptional splice site recognition | Transcription-splicing coupling studies |
| 5' splice site modulators | Modulate U1 snRNP recognition | Mechanistic studies of recognition fidelity |
| 3' splice site associated factors | Facilitate 3' splice site recognition | Functional dissection of 3' splice site selection |
| Long intron splicing factors | Support splicing of long introns | Genome-wide splicing analysis |
| Cryptic splice-polyadenylation regulators | Control cryptic splice-polyadenylation events | Disease modeling of TDP-43 proteinopathies |
| Splice-site variant carriers | Harbor variants affecting splice site recognition | Clinical classification and minigene assays |
| Minor spliceosome U1-like components | Recognize 5' splice site in minor spliceosome | Structural biology of minor spliceosome |
How Is mRNA splice site recognition Regulated?
mRNA splice site recognition is regulated by dynamic U2AF cycling, which defines two phases of cotranscriptional pre-mRNA splicing and couples recognition to transcription. In addition, U1 snRNP binding and modulation provide a regulatory layer for 5' splice site recognition. FUBP1 facilitates 3' splice site recognition and long intron splicing, indicating that accessory factors modulate the efficiency of recognition. Disease-associated perturbations such as TDP-43 dysfunction can redirect recognition to cryptic sites, as shown for STMN2.
mRNA splice site recognition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STMN2 | TDP-43 proteinopathies with cryptic splice-polyadenylation | Knockout or point-mutation models of STMN2 cryptic splice-polyadenylation |
| CHEK2 | Cancer predisposition with splice-site variants | Minigene assays and knock-in of patient variants |
| FUBP1 | Long intron splicing defects | Knockout and overexpression models for 3' splice site recognition |
| U2AF | Cotranscriptional splicing dysregulation | Point-mutation models of U2AF cycling |
| U1 snRNP components | 5' splice site recognition defects | Structural and functional perturbation models |
Neurodegeneration and TDP-43 proteinopathies
TDP-43 proteinopathies involve cryptic splice-polyadenylation of STMN2, and correction of this event has been studied as a therapeutic strategy. This links mRNA splice site recognition defects directly to neurodegeneration. The mechanism of STMN2 cryptic splice-polyadenylation provides a paradigm for how recognition errors produce disease-relevant transcripts.
Cancer predisposition and CHEK2 splice-site variants
Systematic minigene-based splicing analysis and tentative clinical classification of 52 CHEK2 splice-site variants have been performed, highlighting the clinical importance of splice site recognition in cancer predisposition. These variants can affect recognition and thereby CHEK2 function. This work supports functional classification of splice-site variants in hereditary cancer.
Splicing factor dysfunction and long intron genes
FUBP1 facilitates 3' splice site recognition and splicing of long introns, suggesting that its dysfunction may preferentially affect long intron-containing genes. Because long introns are common in neuronal genes, this mechanism is relevant to neurological disease. Dynamic U2AF cycling further links recognition defects to cotranscriptional splicing changes.
From mRNA splice site recognition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for splice site recognition? | CRISPR knockout cell model |
| Does a specific splice-site variant alter recognition? | Point-mutation knock-in model |
| Does a disease variant change isoform usage? | Knock-in of patient variant with RNA-seq readout |
| Where does a factor bind during recognition? | Tagged knock-in for imaging and proteomics |
| Does overexpression of a factor enhance recognition? | Overexpression cell model |
| Which long introns depend on a factor? | Knockout plus long-read RNA-seq |
How to Study the mRNA splice site recognition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Minigene splicing assay | Splice site usage of a variant | Clinical classification of CHEK2 variants |
| RNA-seq | Isoform and cryptic splice-polyadenylation changes | Disease modeling of STMN2 |
| Long-read RNA-seq | Full-length isoform and long intron splicing | FUBP1-dependent long intron analysis |
| Cryo-EM / structural biology | 3D architecture of recognition complexes | U1 snRNP and minor spliceosome studies |
| Biochemical binding assays | RNA-protein interactions during recognition | Mechanistic studies of 5' splice site recognition |
| Cotranscriptional splicing assays | Kinetics of U2AF cycling | Transcription-splicing coupling studies |
| CRISPR knockout | Requirement of a gene for recognition | Functional genomics of splicing factors |
| Proteomics | Composition of recognition complexes | Spliceosome assembly analysis |
Minigene splicing assays
Minigene-based splicing analysis enables functional classification of splice-site variants, as demonstrated for 52 CHEK2 variants. This method directly tests whether a variant affects splice site recognition. It is widely used for clinical interpretation of variants of uncertain significance.
RNA-seq and long-read sequencing
RNA-seq can detect cryptic splice-polyadenylation and isoform changes caused by recognition defects, as shown for STMN2. Long-read sequencing is particularly useful for long intron-containing genes affected by factors such as FUBP1. These approaches quantify the consequences of altered splice site recognition.
Structural and biochemical assays
Structural studies have defined the basis of 5' splice site recognition by the minor spliceosome and the sequential binding mechanism of the human U1 snRNP. Biochemical assays complement these structures by testing binding and modulation. Together they reveal how recognition is achieved at atomic and molecular levels.
Cotranscriptional splicing assays
Dynamic U2AF cycling can be studied using cotranscriptional splicing assays that define two phases of pre-mRNA splicing. These methods link transcription and splice site recognition. They are useful for understanding kinetic control of recognition.
How CRISPR Can Be Used to Study GO:0006376 mRNA splice site recognition
Knockout
CRISPR knockout of splice site recognition factors can test whether a gene is required for commitment/E complex formation and accurate splicing. For example, knocking out FUBP1 can reveal its role in 3' splice site recognition and long intron splicing. Knockout models are also used to study U2AF cycling and cotranscriptional splicing.
Point Mutation
Point-mutation models can mimic patient splice-site variants, such as CHEK2 variants analyzed by minigene assays. These models allow precise testing of how a single nucleotide change affects splice site recognition. They are also useful for dissecting U1 snRNP recognition determinants.
Knock-in
Knock-in of disease-associated variants, such as those affecting STMN2 cryptic splice-polyadenylation, enables study of recognition defects in a native genomic context. Knock-in models can also be used to tag recognition factors for imaging and proteomics. This approach preserves endogenous regulation of splice site recognition.
Overexpression
Overexpression of splicing factors such as FUBP1 can test whether increased levels enhance 3' splice site recognition and long intron splicing. Overexpression models are useful for gain-of-function studies of recognition components. They complement loss-of-function knockout approaches.
How EDITGENE Supports mRNA splice site recognition Research
Researchers studying mRNA splice site recognition-related genes often need to determine whether a candidate gene is causally involved in recognition, how a specific variant alters splice site choice, and which downstream isoforms change. EDITGENE provides CRISPR-based cell models and screening services to address these questions with publication-ready rigor.
Contact EDITGENE today to design your custom CRISPR model for mRNA splice site recognition research.
Frequently Asked Questions About mRNA splice site recognition
What is GO:0006376 mRNA splice site recognition?
GO:0006376 is the biological process defined as selection of a splice site by components of the assembling spliceosome, corresponding to commitment/E complex formation.
What genes are involved in mRNA splice site recognition?
Key genes and factors include U1 snRNP components, U2AF, FUBP1, STMN2, CHEK2, TDP-43, and minor spliceosome components.
How does U1 snRNP recognize the 5' splice site?
The human U1 snRNP uses a sequential binding mechanism for 5' splice site recognition and modulation.
What is the role of U2AF in splice site recognition?
Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing and contributes to 3' splice site recognition.
What does FUBP1 do in splicing?
FUBP1 is a general splicing factor that facilitates 3' splice site recognition and splicing of long introns.
How is STMN2 related to TDP-43 proteinopathies?
STMN2 undergoes cryptic splice-polyadenylation in TDP-43 proteinopathies, and its correction has been studied as a therapeutic approach.
Why are CHEK2 splice-site variants important?
Systematic minigene-based splicing analysis and tentative clinical classification of 52 CHEK2 splice-site variants support their clinical interpretation.
What is the spliceosomal commitment complex?
The commitment complex, also called the E complex, is the early spliceosomal assembly that commits pre-mRNA to splicing during splice site recognition.
How can I study mRNA splice site recognition in the lab?
Common methods include minigene splicing assays, RNA-seq, long-read sequencing, structural biology, and CRISPR knockout or knock-in models.
What is the structural basis of minor spliceosome 5' splice site recognition?
Structural studies have defined the basis of 5' splice site recognition by the minor spliceosome.
Conclusion
GO:0006376 mRNA splice site recognition is the early, decisive step in which the assembling spliceosome selects splice sites and commits pre-mRNA to splicing through the commitment/E complex. It involves U1 snRNP at the 5' splice site, U2AF and FUBP1 at the 3' splice site, and is coupled to transcription via dynamic U2AF cycling. Because defects in this process cause diseases such as TDP-43 proteinopathies and contribute to CHEK2-associated cancer risk, it is a high-value target for functional genomics. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide the tools needed to dissect these mechanisms.
References
- 1. Baughn MW et al.. 2023. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.. Science 379(6637):1140-1149 PMID: 36927019
- 2. Sanoguera-Miralles L et al.. 2024. Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants.. Clin Chem 70(1):319-338 PMID: 37725924
- 3. Ebersberger S et al.. 2023. FUBP1 is a general splicing factor facilitating 3' splice site recognition and splicing of long introns.. Mol Cell 83(15):2653-2672.e15 PMID: 37506698
- 4. Wahl MC et al.. 2009. The spliceosome: design principles of a dynamic RNP machine.. Cell 136(4):701-18 PMID: 19239890
- 5. Shao C et al.. 2025. Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing.. Science 389(6767):eadj9141 PMID: 40997183
- 6. Reed R. 1996. Initial splice-site recognition and pairing during pre-mRNA splicing.. Curr Opin Genet Dev 6(2):215-20 PMID: 8722179
- 7. White DS et al.. 2024. A sequential binding mechanism for 5' splice site recognition and modulation for the human U1 snRNP.. Nat Commun 15(1):8776 PMID: 39389991
- 8. Zhao J et al.. 2025. Structural basis of 5' splice site recognition by the minor spliceosome.. Mol Cell 85(3):652-664.e4 PMID: 39809272
